COVANTA HOLDING CORP Form FWP January 26, 2007

Issuer Free Writing Prospectus Filed by: Covanta Holding Corporation Pursuant to Rule 433 under the Securities Act of 1933 Registration Statement on Form S-3: No. 333-134173 Registration Statement on Form S-3: No. 333-140082

Covanta Holding Corporation
Concurrent Offerings of
5,320,000 Shares of Common Stock
(the Common Stock Offering)
and
\$325,000,000

aggregate principal amount of 1.00% Senior Convertible Debentures due 2027

(the Debentures Offering)

This free writing prospectus relates only to the Common Stock Offering of shares of common stock, par value \$0.10 per share (the Common Stock) and the Debentures Offering of 1.00% Senior Convertible Debentures due 2027 (the Debentures) and should be read together with (1) the preliminary prospectus supplement dated January 19, 2007 relating to the Common Stock Offering (the Common Stock Preliminary Prospectus Supplement) and the prospectus dated May 16, 2006 (the Common Stock Base Prospectus), including the documents incorporated by reference in the Common Stock Preliminary Prospectus Supplement and the Common Stock Base Prospectus and (2) the preliminary prospectus supplement dated January 19, 2007 relating to the Debentures Offering (the Debenture Preliminary Prospectus Supplement) and the prospectus dated January 19, 2007 (the Debenture Base Prospectus), including the documents incorporated by reference in the Debenture Preliminary Prospectus Supplement and the Debenture Base Prospectus.

Issuer: Covanta Holding Corporation

Common Stock symbol: CVA

The Common Stock Offering

Securities: 5,320,000 shares of Common Stock

Over-allotment option: 798,000 shares of Common Stock

Issue price: \$23.50 per share

Closing sale price of stock on

January 25, 2007:

\$23.77 per share

Net proceeds

\$118.3 million (\$136.1 million if the over-allotment option is exercised in full)

(estimated):

Underwriting compensation

per share:

\$1.175

Aggregate underwriting

compensation:

\$6,251,000 (\$7,188,650 if the over-allotment option is exercised in full)

Selling concession

per share:

\$0.71

Trade date: January 25, 2007

Settlement date: January 31, 2007

Underwriters: Lehman Brothers Inc., J.P. Morgan Securities Inc. and Merrill Lynch, Pierce,

Fenner & Smith Incorporated (Joint Book-Running Managers) and Banc of America Securities LLC, Barclays Capital Inc., Pacific Growth Equities, LLC and

UBS Securities LLC (Co-Managers)

The Debentures Offering

Securities: 1.00% Senior Convertible Debentures due 2027

Ratings: B by Standard & Poor s and B1 by Moody s

Aggregate principal amount: \$325,000,000

Over-allotment option: \$48,750,000

Issue price: 100%

Annual interest rate: 1.00%

Issue price of Common Stock

Offering:

\$23.50 per share

Conversion premium over issue

price of Common Stock

Offering:

20.0%

Conversion rate

(subject to adjustment):

35.4610 shares per \$1,000 principal amount of Debentures

Conversion price

\$28.20 per share

(approximately)

(subject to adjustment):

Conversion rights: Subject to fulfillment of certain conditions and during the periods described in the

Debenture Preliminary Prospectus Supplement.

Interest payment dates: February 1 and August 1

First interest payment date: August 1, 2007

Maturity date: February 1, 2027

Contingent interest: Yes, commencing on February 1, 2012

Comparable yield: 7.25%

Call feature: Redeemable on or after February 1, 2012

Puts: February 1, 2012, February 1, 2017 and February 1, 2022

Increase to conversion rate upon a Fundamental Change (subject to adjustment):

	Stock price									
Effective Date	\$23.50	\$28.20	\$30.00	\$35.00	\$40.00	\$45.00	\$50.00	\$55.00	\$60.00	\$65.00
January 31,										
2007	7.0921	4.4158	3.7251	2.3830	1.5723	1.0611	0.7273	0.5030	0.3486	0.2403
February 1,										
2008	7.0921	4.3822	3.6468	2.2458	1.4273	0.9292	0.6152	0.4112	0.2752	0.1828
February 1,										
2009	7.0921	4.2062	3.4277	1.9881	1.1899	0.7308	0.4574	0.2893	0.1829	0.1140
February 1,										
2010	7.0921	3.8428	3.0190	1.5716	0.8416	0.4639	0.2620	0.1502	0.0858	0.0473
February 1,										
2011	7.0914	3.0982	2.2289	0.8745	0.3420	0.1388	0.0607	0.0287	0.0135	0.0048
2007 February 1, 2008 February 1, 2009 February 1, 2010 February 1,	7.0921 7.0921 7.0921	4.3822 4.2062 3.8428	3.6468 3.4277 3.0190	2.2458 1.9881 1.5716	1.4273 1.1899 0.8416	0.9292 0.7308 0.4639	0.6152 0.4574 0.2620	0.4112 0.2893 0.1502	0.2752 0.1829 0.0858	0.18 0.11 0.04

If the stock price per share of Issuer s common stock is:

in excess of \$65.00 per share (subject to adjustment), the conversion rate will not be increased; or

less than \$23.50 per share (subject to adjustment), the conversion rate will not be increased.

Conversion rate cap: 42.5531 shares per \$1,000 principal amount of Debenture

Net proceeds (estimated):

\$314.9 million (\$362.4 million if the over-allotment option is exercised in full)

Underwriting compensation

per Debenture:

\$25

Aggregate underwriting

compensation:

\$8,125,000 (\$9,343,750 if the over-allotment is exercised in full)

Selling concession

per Debenture:

\$15.00

Trade date: January 25, 2007

Settlement date: January 31, 2007

Debenture CUSIP: 22282EAA0

Underwriters: Lehman Brothers Inc., J.P. Morgan Securities Inc. and Merrill Lynch, Pierce,

Fenner & Smith Incorporated (Joint Book-Running Managers) and Banc of America Securities LLC, Barclays Capital Inc. and UBS Securities LLC

(Co-Managers)

The Issuer has filed registration statements (including prospectuses) with the SEC for the Common Stock Offering and the Debenture Offering to which this communication relates. Before you invest, you should read the prospectus in applicable registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and the Common Stock Offering and the Debenture Offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offerings will arrange to send you the applicable prospectus if you request it by calling toll-free 1-888-603-5847.

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED, SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.